ReviewHepatology international2026
Combination therapies for chronic hepatitis B in the era of emerging novel drugs.
Review in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A randomized trial of viral vector and adjuvanted protein HBV therapeutic vaccine in people with chronic hepatitis B on nucleos(t)ide analogs.Hepatology communications · 2026Trial
- Post-Translational Modifications of NTCP: A Regulatory Nexus for Bile Acid Transport and HBV Entry.Biomedicines · 2026Review
- Accuracy of Diagnostic Investigations in Monitoring Hepatitis B Virus Infection: Strengths, Limitations, and Emerging Biomarkers.International journal of molecular sciences · 2026Review
- Hepatocyte-Targeted Drug Delivery Strategies for Chronic Hepatitis B: Overcoming Delivery Barriers Toward Functional Cure.Pharmaceutics · 2026Review
- Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesChronic Hepatitis B (CHB) is a global health concern, affecting hundreds of millions and potentially leading to severe outcomes, such as cirrhosis and hepatocellular carcinoma. The primary treatment goal is to achieve a functional cure-defined as the loss of hepatitis B surface antigen (HBsAg) 24 weeks after the cessation of therapy-which reduces liver inflammation, improves histopathology, and decreases the incidence of end-stage liver disease. However, this goal is rarely achieved with current therapies, especially monotherapies. With a deeper understanding of the HBV lifecycle and its interactions with the host immune system, combination therapy strategies are increasingly demonstrating potential to enhance treatment outcomes for CHB.
methodsThis article reviews the application of novel drugs in combination therapy, analyzes the suitability of different drug combinations, and evaluates their effects on HBsAg clearance rates and overall cure rates.
resultsThe review identified several promising drugs, such as capsid assembly modulators, entry inhibitors, and RNA interference therapies, which demonstrated greater efficacy in combination therapy, achieving higher HBsAg clearance and enhanced immune responses compared to monotherapies. However, effectiveness varied among patient subgroups, highlighting the need for personalized treatment.
conclusionsCombination therapies involving novel drugs hold promise for improving CHB outcomes, particularly in achieving a functional cure. Further research is required to optimize personalized regimens and to assess their long-term safety and efficacy for broader clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.